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Abstract
Background: Urinary tract infections (UTIs) are among the most common bacterial infections. Despite this burden,
there are few studies of the costs of UTIs. The objective of this study was to determine the costs of UTIs in women
over 18 years of age who visit general practitioners in France.
Methods: The direct and indirect costs of clinical UTIs were estimated from societal, French National Health
Insurance and patient perspectives. The study population was derived from a national cross-sectional survey
entitled the Drug-Resistant Urinary Tract Infection (Druti). The Druti included every woman over 18 years of age
who presented with symptoms of UTI and was conducted in France in 2012 and 2013 to estimate the annual
incidence of UTIs due to antibiotic-resistant Enterobacteriaceae in women visiting general practitioners (GPs) for
suspected UTIs.
Results: Of the 538 women included in Druti, 460 were followed over 8 weeks and included in the cost analysis.
The mean age of the women was 46 years old. The median cost of care for one episode of a suspected UTI was
€38, and the mean cost was €70. The annual societal cost was €58 million, and €29 million of this was reimbursed
by the French National Health Insurance system. In 25 % of the cases, the suspected UTIs were associated with
negative urine cultures. The societal cost of these suspected UTIs with negative urine cultures was €13.5 million.
No significant difference was found between the costs of the UTIs due to antibiotic-resistant E. coli and those due
to wild E. coli (p = 0.63).
Conclusion: In the current context in which the care costs are continually increasing, the results of this study
suggests that it is possible to decrease the cost of UTIs by reducing the costs of suspected UTIs and unnecessary
treatments, as well as limiting the use of non-recommended tests.
Keywords: Urinary tract infection, Cost of illness, Primary care
Background
Urinary tract infections (UTIs) are among the most
common bacterial infections [1] and affect nearly half of
all women at least once in their lives [2]. Women are more
affected than men and exhibit two incidence peaks, i.e.,
early in the period of sexual activity and in the postmeno-
pausal period [3]. Among those aged 18 years and over,
10.8 % of women reported having at least one UTI within
the past 12 months [4]. Escherichia coli (E. coli) is the
most common urinary pathogen and is found in 74 % of
outpatient UTIs [5]. Antimicrobial resistance is increasing
and varies between countries, and this variation is strongly
related to antibiotic prescription practices [6–9].
Initial E. coli UTI episodes are followed in 44 % of
cases by recurrence within 12 months [10].
Despite this burden, few studies have examined the
costs of UTIs. In 1997, an American study estimated
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that the burden of UTIs represented 100,000 hospitaliza-
tions, 7 million visits and 1 million admissions to emer-
gency services [11]. In 1995, UTI costs were estimated at
$1.6 billion in the USA ($659 million in direct costs and
$936 million in indirect costs) [4]. The direct cost per
patient has been estimated to be between 112 and 172
dollars [12]. In France, these costs are unknown. The main
objective of this study was to calculate the direct and
indirect UTI costs (including cystitis and acute pyeloneph-
ritis) in women over 18 years of age who visit general
practices in France. The secondary objectives were to
calculate the costs of suspected UTIs with negative urine
cultures and to compare the costs of UTIs due to antibiotic-
resistant E. coli with those of UTIs due to wild E. coli.
Methods
Population
The data were collected during the Drug Resistance in
Community Urinary Tract Infection (Druti) survey. The
Druti was a national cross-sectional survey that was
conducted in France between January 2012 and February
2013 by general practitioners (GP) of the Sentinelles
network [13]. The aim of this survey was to estimate the
annual incidence of UTIs due to antibiotic-resistant bac-
teria in women who visited GPs for suspected UTIs [14].
A two-stage sampling design that has been described else-
where [14] was applied. The eligible patients were females
over 18 years old who presented within the previous 7 days
with at least one of the following symptoms: dysuria and
frequent or urgent of urination (Additional file 1). The
patients who agreed to participate and had not taken antibi-
otics within the prior 7 days were included.
Data available
For each patient, a urine sample was collected, and urine
cultures were performed on all samples in the same
laboratory. The urine samples were analyzed, and the
antimicrobial susceptibilities were tested. The bacterio-
logical methods are described elsewhere [15, 16]. The
GPs were blinded to the urine culture results. When
needed, the GPs prescribed another urine culture.
The included patients completed an inclusion
questionnaire that contained the patients’ characteristics
(i.e., age, clinical status (chronic diseases and comorbidi-
ties) and socio-economic data) (Additional file 2). The
women completed a questionnaire within 8 weeks
following inclusion in which they specified the daily
presence or absence of symptoms within the first 14 days
(Additional file 3). The women provided information
about their health care usage (e.g., physician visits,
diagnostic tests, prescription drugs and hospitalization)
and sick leave from the baseline time point to 8 weeks.
A research assistant contacted by phone the women at
two and 8 weeks to collect the data.
Costs
The direct and indirect costs of clinical UTIs were
estimated from the societal perspective, the French
National Health Insurance perspective and the patient
perspective (prior to private complementary health
insurance participation) [17].
French National Health Insurance covers the costs of
general and specialized medical visits, prescription
drugs, diagnostic tests and hospitalizations. In cases of
sickness, the insurance also provides daily allowances for
economically active persons, insured and unable to
work. Private health insurance can be utilized to reim-
burse patients for health-related costs that are not cov-
ered by social security. For the most disadvantaged,
state-run programs provide universal health coverage.
The patient contribution corresponds to the costs that
are not covered by the French National Health Insur-
ance and the patient’s private health insurance.
Only the costs of the initial UTI episode and associ-
ated relapses were taken into account. The costs related
to reinfection were not included. The definitions of
relapse and reinfection were based on those in the litera-
ture [2, 18, 19]. All costs were calculated based on the
reported data declared by the women.
The costs are presented in euros. In 2012, the Purchas-
ing Power Parities (i.e., the rates of currency conversion
that eliminate the differences in price levels between
countries) were $1.1718 and ₤0.8145 for €1 [20].
1. Direct costs
Direct costs include direct medical costs related to
physician visits, diagnostic tests, prescription drugs
and hospitalizations [21].
– Physician visits. All physician visits were
considered including GP visits at baseline. In 2012,
the average cost for a physician visit for a woman
was determined based on the General Sample of
Beneficiaries (EGB), which is permanent
representative sample of the population that is
protected by the French National Health Insurance
[22]. This cost was estimated according to medical
specialty and department of residence and was
available for the societal, French National Health
Insurance and patient perspectives. The French
National Health Insurance paid for 70 % of the
costs of physician visits.
– Diagnostic tests. Only tests performed for UTIs
were considered. The costs of the urine cultures
that were performed for the incidence study were
not included in the analysis. The Nomenclature
of Medical Biology Acts (NABM) was used to
determine the costs of bio-medical analysis, and
the Common Classification of Medical Acts
(CCAM) was used to determine the costs of
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medical imaging procedures. When a patient did
not provide the exact title of the diagnostic test,
the weighted mean of the cost of same family of
investigations (e.g., blood tests or ultrasound) was
used. The French National Health Insurance paid
for 60 % of the costs of the bio-medical analyses
and 70 % of the costs of the medical imaging
procedures.
– Prescription drugs. Only treatments related to
UTIs that were prescribed by a physician and
partially (65, 35 or 15 % according to the drug)
or totally paid for by the French National Health
Insurance were considered. Over the counter
drugs dispensed by pharmacists were not taken
into account. Two French National Health
Insurance databases were used, i.e., the drug’s
database (which contains baselines for allopathic
medicines that are reimbursed by health
insurance) and the MEDICAM (which contains
detailed information about reimbursed drugs) [23,
24]. These databases contained the costs of each
box of drug (per molecule and by strength,
packaging and laboratory), the number of boxes
sold and the amount paid by the French National
Health Insurance system in 2012. Pediatric and
injectable (except third-generation cephalosporin)
drugs were removed before the analysis. The
average costs weighted by the number of boxes
sold in 2012 per molecule and by strength and
packaging were calculated. The prescriptions
provided the physicians at baseline were used to
determine the average cost of a prescription per
molecule. This cost was then related to the
patient-declared drug consumption.
– Hospitalizations. Only admissions related to UTIs
were considered. The hospitalizations cost was
defined based on the Hospital Stay-Related Group
(GHS), which is classification of hospital stays that
is based on the care delivered to patients. A tariff
order defined by the government was used to
determine the cost of the GHS [25]. The GHS were
determined based on the patient’s age, disease and
medical history [26]. This information was recov-
ered from hospitalization reports that were ob-
tained directly from hospital after acquiring the
patient’s consent. The French National Health In-
surance reimbursed 80 % of the GHS.
2. Indirect costs
The indirect costs included only morbidity costs
(loss of productivity due to absenteeism) [21]. The
friction costs method was used to account for the
ability of a company to adapt to the absence of an
employee [27]. An elasticity of 0.8 was applied. The
daily productivity lost (or gross daily pay) for each
women by socio-professional category was obtained
by multiplying the gross hourly pay in 2010 based on
data from the French National Institute of Statistics
and Economic Studies (INSEE) [28] with the number
of hours worked per day by a full time equivalent
[29]. Next, the employer’s contributions (32.85 % of
gross pay) were added [17, 30, 31]. In 2010, the aver-
age gross hourly pays were null for non-economically
active persons (i.e. students, unemployed person and
retired person), €19.42 for manual workers, €21.06
for clerical workers, €29.77 for intermediate occupa-
tions and €42.57 for managers.
The French National Health Insurance pays patient
daily allowances that represent 50 % of the gross
daily pay [32, 33] only from the fourth day of the
sick leave until the end of the sick leave. The daily
allowance amounts were also calculated based on
the women’s gross hourly pay according to
socio-professional category [28]. On the first of
January 2012, the daily allowances were capped at
€42.77. The patient loss of income was taken as
the net daily pay for the first 3 days off, and the
difference between the net daily pay and the daily
allowances for the following days.
Economic and statistical analysis
The sampling design (stratification, stages and sampling
weights) was taken into account in all of the analyses to
make inferences about the population and has been
described elsewhere [14]. The average costs of clinical
UTIs in France were calculated according to expense
items (physician visits, diagnostic tests, prescription
drugs, hospitalizations and productivity losses). The total
costs according to expense items were calculated by
multiplying the average costs by the estimated number
of visits to general practices for UTIs in 2012. The mean
costs of suspected UTIs that were confirmed and uncon-
firmed based on urine cultures were compared with
Student’s t-tests as were the mean UTIs costs due to
wild and antibiotic-resistance E. coli.
For the analysis, the E. coli were classified as resistant
based on disclosed resistance or intermediate suscepti-
bility to a particular antimicrobial agent; otherwise, the
isolate was classified as susceptible. Multi-resistance was
defined as acquired resistance to at least three classes of
antibiotic [34].
The data management and analyses were performed
using the R version 2.10.1 software especially the Survey
package [35, 36].
Results
Population and urine cultures
During the study, 87 GPs enrolled 1,569 women who vis-
ited with symptoms of UTI. Among these women, 538
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were included, and 460 were followed for 8 weeks (Fig. 1).
The mean age of the GPs was 53 years (ranging from 33
to 65), and 12 % were women. The mean ages of the
eligible women and the women who were followed for 8
weeks were 47 and 46 years, respectively. The women
who were followed for 8 weeks had more dysuria and
pelvic or flank pain than the eligible women (Table 1).
There were more clerical workers and managers and less
non-economically active persons in our population than is
the general population (Table 2). Of the 460 followed
women, 55 remained symptomatic after 2 weeks (12 %).
Complicated UTIs represented 25 % [21–29] of UTI
cases. Women treated for a chronic disease (diabetes,
cancer or renal insufficiency), pregnancy and urinary
tract anomalies represented 6 % [4–8], 2 % [1–3], and
4 % [2–6] of UTI cases, respectively.
The number of visits to general practices for suspected
UTIs was estimated to be 823,073 among over the age
of 18 years in 2012 (95 % confidence interval (CI):
623,614–1,040,532). Among these clinical UTIs, 626,046
(95 % CI: 465,196–786,896) were confirmed by positive
urine cultures, and 518,446 (95 % CI: 381,981–654,911)
of these UTIs were due to E. coli.
UTIs costs
Physician visits
After inclusion, 14 % (95 % CI: 10–20 %) of the women
had further visits with a GP, an urologist or a gynecologist
(Table 3). The mean costs per patient were €27.69 (95 %
CI: €25.81–29.56) from the societal perspective and
€17.44 (95 % CI: €16.27–18.6) from the French National
Health Insurance perspective.
Diagnostic tests
At least one diagnostic test was performed for 29 % of
the women (95 % CI: 22–36 %) including 24 % (95 % CI:
18–31 %) of women who underwent a urine culture and
8 % (95 % CI: 5–12 %) who underwent an ultrasound
(Table 3). Nine percent (95 CI: 0–19 %) of women who
underwent an ultrasound had a history of urinary tract
abnormality. The mean costs per patient were €11.54
(95 % CI: €8.81–14.26) from the societal perspective and
€7.27 (95 % CI: €5.54–8.99) from the French National
Health Insurance perspective. Among these tests, 52 %
(95 % CI: 43–60 %) were performed outside of the
French recommendations.
Fig. 1 Flow chart
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Prescription drugs
Antibiotics were prescribed to 98 % (95 % CI: 96–99 %)
of the women. Other treatments (i.e., analgesics, antifun-
gals, digestive transit regulators, hormonal treatments,
proton pump inhibitors with non-steroidal anti-
inflammatory drugs and corticosteroids for cases with
antibiotic allergies) were prescribed to 17 % (95 % CI:
13–22 %) of the women (Table 3). The mean costs per
patient were €12.68 (95 % CI: €11.53–13.83) from the
societal perspective and €7.30 (95 % CI: €6.60–8.01)
from the French National Health Insurance perspective.
Hospitalization
Only one patient in this study was hospitalized for
pyelonephritis. This hospitalization cost was €1240.67
(Table 3). The mean costs were patient was €1.13 (95 %
CI: €0–3.28) from the societal perspective and €0.86
(95 % CI: €0–2.51) from the French National Health
Insurance perspective.
Indirect costs
Nine percent of the women (95 % CI: 7–13 %) took sick
leaves. Among these women, 15 % (95 % CI: 6–32 %)
took sick leaves longer than 3 days and received daily al-
lowances from the French National Health Insurance.
The mean sick leave duration was 2.39 days (95 % CI:
1.62–3.15) (Table 4). The mean costs per patient were
€16.71 (95 % CI: €8.79–24.63) from the societal perspec-
tive and €1.63 (95 % CI: €0–3.34) from the French Na-
tional Health Insurance perspective.
Overall in France in 2012, the mean global cost for a
suspected UTI episode was €69.73 (95 % CI: €58.54–
€80.92) for women over 18 years of age who visited a
GP, and the median cost was €37.74 (Table 5). Based on
the estimation of 823,073 visits for UTI views in general
practices in 2012, the annual total cost of suspected
UTIs was €58 million.
Costs of suspected UTIs with negative urine cultures
Among the urine cultures, 75 % (95 % CI: 70–79 %)
were positive. E. coli was the most common pathogen
(77.4 %; 95 % CI: 73–81 %). The care consumptions
were similar among women with positive and negative
urine cultures. The mean cost per patient did not signifi-
cantly differ between the two groups, i.e., €70.96 (95 %
CI: €58.99–82.92) for the women with positive urine cul-
tures and €66.13 (95 % CI: €48.39–83.87) for the women
with negative urine cultures (p = 0.60). From the societal
perspective, the total cost of suspected UTIs with nega-
tive urine cultures was €13.6 million (23 % of the total
UTI costs).
Mean costs of UTIs due to antibiotic-resistant E. coli and
wild E. coli
Among the E. coli-positive urine cultures, 38 % (95 %
CI: 31–45 %) were resistant to at least one antibiotic,
and 19 % (15–24 %) were multi-resistant. The care
consumptions were similar for the women infected with
resistant and wild E. coli. The mean cost per patient for
UTIs due to wild E. coli was €74.76 (95 % CI: €57.61–
91.91), which did not significantly differ from the mean
UTI cost due to E. coli strains that were resistant to
at least one antibiotic (€67.44; 95 % CI: €43.93–90.95;
p = 0.63) or the mean UTI cost due to multi-resistant
E. coli (€74.49; 95 % CI: €30.87–118.11; p = 0.99).
Table 1 Characteristics of the eligible women and the women who were followed for 8 weeks
Eligible patients n = 1,569 Patients followed for 8 weeks, n = 460 p value*
Age (mean, sd) 47 (19) 46 (17) 0.37
Urinary tract infection symptoms (n, %)
Dysuria 1,431 (91 %) 432 (94 %) 0.08
Frequent urination 1,386 (88 %) 421 (92 %) 0.08
Urinary urgency 1,044 (67 %) 340 (74 %) 0.004
Hematuria 357 (23 %) 121 (26 %) 0.15
Pelvic of lower back pain 582 (37 %) 198 (43 %) 0.031
Fewer 112 (7 %) 32 (7 %) 0.87
*chi-square or Student t-test
Table 2 Socio-economic status of included women and French
women in general population
Percentage of
patients followed
for 8 weeks,
n = 460
Percentage for
women in general
population
p value*
Manual workers 3.7 5.1 0.17
Clerical workers 33.3 23.5 <0.0001
Intermediate
occupations
15 14.9 0.56
Managers 12.6 7.4 <0.0001
Non-
economically
active persons
35.43 49.1 <0.0001
François et al. BMC Health Services Research  (2016) 16:365 Page 5 of 10
Discussion
This initial study conducted in France on the costs of
community UTIs in women over 18 years of age esti-
mated a total cost from the societal perspective of €58
million in 2012, €44 million for direct costs and €14 mil-
lion for indirect costs. Half of this cost was supported by
the French National Health Insurance, and half was sup-
ported by the patients (before private complementary
health insurance participation). Visits represented the
largest expense item followed by sick leave and prescrip-
tion drugs. Although very expensive, hospitalizations
were rare and therefore represented the smallest expense
item. The costs for 75 % of the women were below the
mean cost. Additional visits with specialist physicians,
ultrasounds, hospitalizations and sick leave concerned
less than one quarter of the women. The important costs
of these additional health care procedures clearly
increased the mean UTI cost.
An important strength of this study was the use of a
sampling design. This allowed to correct the bias due to
drop-outs and geographical repartition and to generalize
with caution the cost of UTIs to the population of
women over 18 years of age who visit GPs for presumed
UTIs. Furthermore, to estimate the possible costs
according to expense items as accurately as possible, the
maximum amounts of data from the French National
Table 4 Morbidity costs: Loss of productivity due to absenteeism due to urinary tract infection (UTI) in France
Societal perspective French National Health Insurance perspective
Estimated proportion of patients
with sick leave (% (95 % CI))a
Sick leave daily
cost (euros)
Estimated proportion of
patients with sick leave
longer than 3 days
Daily allowances
daily cost (euros)
Women visiting GP for suspected UTI 9 % (7–13 %) 1 % (0.6–3 %)
−Manual worker 0.3 % (0.04–2 %) 76.89 0.05 % (0.01–0.1 %) 29.21
−Clerical workers 5 % (3–8 %) 82.73 1 % (0.03–3 %) 31.78
−Intermediate occupations 3 % (1–5 %) 116.89 0.1 % (0.2–1 %) 42.77
−Managers 1 % (0.3–2 %) 188.91 0.1 % (0.02–1 %) 42.77
Total cost (million euros) 13.9 1.4
Source: French National Institute of Statistics and Economic Studies (INSEE)
aestimated proportion with the sampling design and 95 % CI; CI: confidence interval
Table 3 Direct UTI costs in France
Estimated proportion
of patients consuming
at least one care modalityc
Mean cost per
care modalityc
Societal cost
(millions €)
French National
Health Insurance
cost (millions €)
Patient dost
(before private
complementary
millions €)
All visits GP
(after inclusion)
13 % (9–19 %) 23,72 (23,67–23,77) 23.0 14.5 8.5
Gynecologist 1 % (0.4–3 %) 40,68 (39,93–41,44)
Urologist 0.4 % (0.06–2 %) 56,71 (52,16–61,26)
Diagnostic tests Blood test 2.5 % (1–5 %) 13,50 (11,38–15,64) 9.6 6.0 3.6
Urine culture 24 % (18–31 %) 17,55d
Ultrasound 8 % (5–12 %) 67,29 (63,84–70,73)
Urology scan 0.3 % (0.1–2 %) 150,77
Prescription drugs Fosfomycin 39 % (30–49 %) 8.36d 10.5 6.1 4.4
Other antibiotica 64 % (55–73 %) 13.27 (12.37–14.17)
Analgesics 13 % (10–17 %) 3.98 (3.70–4.27)
Other prescriptionsb 4 % (2–8 %) 5.17 (4.39–5.95)
Hospitalization 0.06 % (0.01–1.2 %) 1294.67 0.9 0.7 0.2
Sources: General Sample of Beneficiaries (EGB), Nomenclature of Medical Biology Acts (NABM) and Common Classification of Medical Acts (CCAM), drug base
(base de medicaments) and MEDICAM
€ euros
aamoxicillin, amoxicillin – clavulanic acid, cefixime, cefpodoxime, ceftriaxone, ciproloxacine, enoxacine, lomefloxacin, nirofurantoin, norfloxacin, nystatin, oxfloxacin,
pefloxacin, nalidixic acid, trimethoprim-sulphamethoxazole
bAntifungals, digestive transit regulators, hormonal treatments, proton pump inhibitors with non-steroidal anti-inflammatory drugs and corticosteroids
cEstimated proportion or mean cost (95 % CI, CI: confidence interval) with the sampling design
dNo 95 % CI due to exact cost
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Health Insurance and the French National Institute of
Statistics and Economic Studies were used. The use of
the EGB allowed for the accounting of possible differ-
ences in care consumption according to gender and
excess fees according to medical specialties and French
departments, particularly in terms of the costs of phys-
ician visits [37]. The systematic collection of urine sam-
ple from all women who visited their GPs for suspected
UTIs permitted the distinction between clinical UTIs
with positive urine cultures from clinical UTIs with
negative urine cultures and the estimation of their re-
lated costs. Furthermore, to estimate the real cost, the
women’ declarations were preferred to the GPs’ declar-
ation to account only for prescriptions that were actually
utilized or purchased.
This study has some limitations that might have resulted
in the over- or underestimation of the costs of UTIs. First,
the cost generalization should be interpreted with caution:
women suffering from UTIs without dysuria, frequent or
urgent of urination were not included, which could
decrease the estimated cost of UTIs; patients included had
more symptoms than eligible patients, which could influ-
ence the achievement of diagnostic test, especially lower
back pain with suspected pyelonephritis; the socio
economic status was not available for eligible women, pre-
venting to compare eligible and included patients on this
point. However, in our study, there were more workers and
less non-economically active persons than in the general
population. This is concordant with the French inequalities
of health care recourse: unemployed and retired persons
seek less care than economically active persons [38].
Second, the costs calculated in this study were for women
who visited GPs and not for the general population. The
estimation of the costs of UTIs among the general popula-
tion would have required the estimations of the costs of
women who visited hospital emergencies departments and
specialists (i.e., urologists and gynecologists). Third, the
data used to estimate the non-medical direct costs (i.e.,
time lost and monetary expenses), intangible costs (i.e., loss
of well-being for the patient and her close family and
friends) and presenteeism costs (i.e., the loss of productiv-
ity due to a UTI while the patient was working) were not
available. Fourth, the friction cost method was chosen to
determinate the indirect costs. The cost’s results should be
interpreted with caution because this method is controver-
sial in cases of short-term disease. The human capital ap-
proach overstates the production lost because the sick
employee’s colleagues can offset the absence via increased
productivity [27]. Consequently, the estimates of friction
costs should represent the upper bound of the estimates of
the short-term indirect costs [27]. However, in cases in-
volving teamwork, the absence of an employee can also re-
duce the production of several employees [39]. Fifth,
although the study was designed to exclude the costs of
reinfection, the women who were symptomatic at 2 weeks
might have experienced a reinfection between the second
and the eighth weeks, and these costs were taken into
account because differences between relapses and reinfec-
tions could not be identified during this period. Sixth, the
costs of long-term symptomatic failure (i.e., the persistence
of symptoms after 8 weeks) could not be taken into
account because the follow-up period stopped after 8
weeks. Seventh, from the patient perspective, the costs
could have been overestimated because some companies
might have paid their employees during their sick leaves;
or these costs could also have been underestimated be-
cause there were no data from which excess fees for med-
ical imaging procedures could be assessed. Another point
from the patient perspective is the costs of over the coun-
ter drugs, which could not still have been accounted for
because costs differ between retail outlets. None of these
data were available. As last limitation, the results of diag-
nostic tests prescribed by physicians were not collected.
According to Foxman [4], 10.8 % of women over 18 years
of age experience at least one UTI per year, which repre-
sents more than 2.5 million people in France as of 1
January 2012 [40]. In our study, the estimated number of
women who visited a GP for a UTI was estimated to
832,073 (95 % CI = 623,614–1,040,532) in 2012. However,
the rate of care seeking for UTIs in France is unknown.
Some women with UTI symptoms might have spontan-
eously recovered healed [41], visited other specialists (e.g.,
gynecologists and urologists) or emergency departments.
The yearly number of emergency visits for UTIs is esti-
mated to 410 000 (2.3 % of the 18 million of emergency
visits), half less than in primary care [42, 43].
In Italy, the mean annual direct cystitis cost (i.e.,
physician visits, diagnostic tests and prescription drugs)
from the Italian National Health Service (NHS) perspec-
tive was evaluated to be €229 per patient between
January 2007 and December 2010 [44]. Each patient had
an average of 4.5 episodes per year. The cost for the
Italian NHS was higher than the cost for the French
National Health Insurance. However, the women
Table 5 Mean urinary tract infection costs per patient from the
perspectives (in euros)
Societal
perspective
French National Health
Insurance perspective
Patients
perspectivea
Mean cost
(95 % confidence
interval)
70 (59–81) 34.50 (31–38) 34 (27–42)
25th percentile 31.68 19.75 11.73
50th percentile 37.74 23.58 15.10
75th percentile 60.86 32.52 24.34
Total cost
(million euros)
58 29 29
aBefore private complementary reimbursement
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included in the Italian study visited referral centers for
the treatment of cystitis, which might have resulted in
the selection of more complicated UTIs. In the United
Kingdom, a cost analysis was performed to evaluate the
mean monthly direct UTIs costs in women between the
ages of 18 and 70 years who were seen by a GP or a
nurse between 2005 and 2006 from the NHS perspec-
tive. The mean monthly direct UTI costs were estimated
at £30.60 when the UTIs were treated with empirical
antibiotic therapy and £37.10 when urine cultures were
performed [45]. The cost differences between this study
and the present French study may have been related to
the systematic one-month follow-up (with no differences
between relapse and reinfection) used in the English
study and the higher remuneration of English GPs
(approximately 30 % greater than that of French GPs in
2008 [46]). In the United States in 2010, the annual
direct and indirect UTI cost was estimated at $2.3
billion [47]. Considering that the American population
was approximately five times greater than the French
population in 2012, the American cost was six times
greater than the French cost. This difference could be
explained by the costs of physician visits and diagnostic
tests, which are three to ten times more expensive in the
United States than in France [48]. Cost-effectiveness
studies have found that most cost-effective treatment is
the empirical use of antibiotics that are effective against
E. coli [12, 49, 50]. Furthermore, in the present French
study, the mean UTI cost due to wild E. coli was not
significantly different from the mean UTI cost due to
antibiotic-resistant E. coli. This lack of a difference could
have resulted from our use of systematic urine analyses.
Even without antibiotics, 20 % of women recover from
uncomplicated lower UTIs within 3 days and 26 %
recover within one week [41, 51]. The effect of inad-
equate antibiotic prescription should be studied in
greater detail and might have little influence on the con-
sumption of care by women who visit GPs for UTIs.
Approximately one quarter of the suspected UTIs seen
in general practice had negative urine cultures. This
illustrates the limits of the clinical diagnosis of urinary
tract infections. The probability of having an UTI for a
woman with urinary symptoms is 48 % [52]; this prob-
ability increases if dysuria, urinary frequency or
hematuria is present [53]. This suspected UTIs with
negative urine cultures had a significant influence on
cost, i.e., more than 23 % of the overall UTI cost. The
environmental influence of antibiotic therapy for these
women cannot be neglected due to the risk of the se-
lection of resistant bacteria [54]. More than half of
diagnostic tests performed for UTIs were prescribed
outside of the recommendations as previously reported
by other authors [55]. It is interesting to consider how
to the prescription of potentially unnecessary and
environmentally harmful treatments the administra-
tion of potentially inappropriate diagnostic tests can be
prevented.
Conclusions
In the current economic context in which the costs of
care are continually increasing, the present study esti-
mated that the cost of UTIs among women who visited
their GPs was €58 million from the societal perspective,
and half of this value was reimbursed by the French
National Health Insurance. This study provides new per-
spectives regarding the possibility of reducing the cost of
the management of this pathology without reducing the
quality of care, particularly via the prescription of diag-
nostic tests. For women with negative urine cultures, the
development of new effective diagnostic tools could re-
duce antibiotic prescriptions and the costs of these
UTIs. Another study should be performed to estimate
the total UTI costs in France that includes the costs of
women who visit hospital emergencies departments and
specialists (e.g., urologists and gynecologists).
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